Photocure ASA: Results for the fourth quarter of 2017

Medical Device Investing

Photocure ASA (OSE:PHO), today reported a revenue growth of 27% for the important U.S. market in the fourth quarter of 2017, contributing to Hexvix®/Cysview® revenues of NOK 39.4 million (Q4 2016: NOK 31.6) and an EBITDA of NOK 0.9 million for the commercial franchise. With the reimbursement of Blue Light Cystoscopy with Cysview for Medicare patients …

Photocure ASA (OSE:PHO), today reported a revenue growth of 27% for the important U.S. market in the fourth quarter of 2017, contributing to Hexvix^®/Cysview^® revenues of NOK 39.4 million (Q4 2016: NOK 31.6) and an EBITDA of NOK 0.9 million for the commercial franchise. With the reimbursement of Blue Light Cystoscopy with Cysview for Medicare patients and FDA approval of label expansion for Cysview, the company expects a continued solid growth towards the 2020 ambitions.

As quoted in the press release:

“In line with previous quarters in 2017, the fourth quarter also demonstrated continued significant progress in our U.S. business. With the two recent major achievements, new reimbursement of Blue Light Cystoscopy with Cysview for Medicare patients and FDA approval of label expansion for Cysview, we have significantly strengthened our possibility to provide many more bladder cancer patients with improved management,” says Kjetil Hestdal, President and Chief Executive Officer of Photocure.

Click here to read the full press release.

approval cancer fda fda approval patients q4 2016 reimbursement Medical Device Investing